These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 36766762)

  • 1. Inhibition of Abl Kinase by Imatinib Can Rescue the Compromised Barrier Function of 22q11.2DS Patient-iPSC-Derived Blood-Brain Barriers.
    Li Y; Sun Z; Zhu H; Sun Y; Shteyman DB; Markx S; Leong KW; Xu B; Fu BM
    Cells; 2023 Jan; 12(3):. PubMed ID: 36766762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of Neurodevelopmental Deficits of 22 q11.2 Deletion Syndrome with a Patient-iPSC-Derived Blood-Brain Barrier Model.
    Li Y; Xia Y; Zhu H; Luu E; Huang G; Sun Y; Sun K; Markx S; Leong KW; Xu B; Fu BM
    Cells; 2021 Sep; 10(10):. PubMed ID: 34685556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complete Sequence of the 22q11.2 Allele in 1,053 Subjects with 22q11.2 Deletion Syndrome Reveals Modifiers of Conotruncal Heart Defects.
    Zhao Y; Diacou A; Johnston HR; Musfee FI; McDonald-McGinn DM; McGinn D; Crowley TB; Repetto GM; Swillen A; Breckpot J; Vermeesch JR; Kates WR; Digilio MC; Unolt M; Marino B; Pontillo M; Armando M; Di Fabio F; Vicari S; van den Bree M; Moss H; Owen MJ; Murphy KC; Murphy CM; Murphy D; Schoch K; Shashi V; Tassone F; Simon TJ; Shprintzen RJ; Campbell L; Philip N; Heine-Suñer D; García-Miñaúr S; Fernández L; ; Bearden CE; Vingerhoets C; van Amelsvoort T; Eliez S; Schneider M; Vorstman JAS; Gothelf D; Zackai E; Agopian AJ; Gur RE; Bassett AS; Emanuel BS; Goldmuntz E; Mitchell LE; Wang T; Morrow BE
    Am J Hum Genet; 2020 Jan; 106(1):26-40. PubMed ID: 31870554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Central 22q11.2 deletion (LCR22 B-D) in a fetus with severe fetal growth restriction and a mother with severe systemic lupus erythematosus: Further evidence of CRKL haploinsufficiency in the pathogenesis of 22q11.2 deletion syndrome.
    Lin I; Afshar Y; Goldstein J; Grossman J; Grody WW; Quintero-Rivera F
    Am J Med Genet A; 2021 Oct; 185(10):3042-3047. PubMed ID: 34196458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arg mediates LPS-induced disruption of the pulmonary endothelial barrier.
    Rizzo AN; Belvitch P; Demeritte R; Garcia JGN; Letsiou E; Dudek SM
    Vascul Pharmacol; 2020; 128-129():106677. PubMed ID: 32240815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood brain barrier permeability increases with age in individuals with 22q11.2 deletion syndrome.
    Taler M; Mekori-Domachevsky E; Vergaelen E; Claes S; Serur Y; Dar S; Levy-Shraga Y; Weizman A; Swillen A; Gothelf D
    World J Biol Psychiatry; 2022 Jul; 23(6):475-482. PubMed ID: 34854358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Matrix stiffness regulates the tight junction phenotypes and local barrier properties in tricellular regions in an iPSC-derived BBB model.
    Yan L; Dwiggins CW; Moriarty RA; Jung JW; Gupta U; Brandon KD; Stroka KM
    Acta Biomater; 2023 Sep; 167():109-120. PubMed ID: 37302732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterozygosity of murine Crkl does not recapitulate behavioral dimensions of human 22q11.2 hemizygosity.
    Yamauchi T; Kang G; Hiroi N
    Genes Brain Behav; 2021 Jun; 20(5):e12719. PubMed ID: 33269541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical significance of CRKL protein phosphorylation level in the treatment of chronic myeloid leukemia with imatinib].
    Xu N; Ouyang Z; DU QF; Wang S; Yang J; Wang Y; Liu XL
    Zhonghua Xue Ye Xue Za Zhi; 2011 Jan; 32(1):25-8. PubMed ID: 21429397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein kinase G increases antioxidant function in lung microvascular endothelial cells by inhibiting the c-Abl tyrosine kinase.
    Stephens RS; Servinsky LE; Rentsendorj O; Kolb TM; Pfeifer A; Pearse DB
    Am J Physiol Cell Physiol; 2014 Mar; 306(6):C559-69. PubMed ID: 24401847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abl family kinases regulate endothelial barrier function in vitro and in mice.
    Chislock EM; Pendergast AM
    PLoS One; 2013; 8(12):e85231. PubMed ID: 24367707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crkl deficiency disrupts Fgf8 signaling in a mouse model of 22q11 deletion syndromes.
    Moon AM; Guris DL; Seo JH; Li L; Hammond J; Talbot A; Imamoto A
    Dev Cell; 2006 Jan; 10(1):71-80. PubMed ID: 16399079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells.
    Lernoux M; Schnekenburger M; Losson H; Vermeulen K; Hahn H; Gérard D; Lee JY; Mazumder A; Ahamed M; Christov C; Kim DW; Dicato M; Bormans G; Han BW; Diederich M
    Clin Epigenetics; 2020 May; 12(1):69. PubMed ID: 32430012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Curcumin derivative C817 inhibits proliferation of imatinib-resistant chronic myeloid leukemia cells with wild-type or mutant Bcr-Abl in vitro.
    Wu LX; Wu Y; Chen RJ; Liu Y; Huang LS; Lou LG; Zheng ZH; Chen YZ; Xu JH
    Acta Pharmacol Sin; 2014 Mar; 35(3):401-9. PubMed ID: 24487968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML).
    Lu T; Cao J; Zou F; Li X; Wang A; Wang W; Liang H; Liu Q; Hu C; Chen C; Hu Z; Wang W; Li L; Ge J; Shen Y; Ren T; Liu J; Xia R; Liu Q
    Eur J Pharmacol; 2021 Apr; 897():173944. PubMed ID: 33581133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia.
    Bandyopadhyay S; Li J; Traer E; Tyner JW; Zhou A; Oh ST; Cheng JX
    PLoS One; 2017; 12(7):e0179558. PubMed ID: 28719608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the tyrosine kinase inhibitor imatinib mesylate on a Bcr-Abl-positive cell line: suppression of autonomous cell growth but no effect on decreased adhesive property and morphological changes.
    Nishihara T; Miura Y; Tohyama Y; Mizutani C; Hishita T; Ichiyama S; Uchiyama T; Tohyama K
    Int J Hematol; 2003 Oct; 78(3):233-40. PubMed ID: 14604282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. circCRKL, a circRNA derived from CRKL, regulates BCR-ABL via sponging miR-877-5p to promote chronic myeloid leukemia cell proliferation.
    Wang J; Liang Y; Qin Y; Jiang G; Peng Y; Feng W
    J Transl Med; 2022 Sep; 20(1):395. PubMed ID: 36058922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [MET/ERK and MET/JNK Pathway Activation Is Involved in BCR-ABL Inhibitor-resistance in Chronic Myeloid Leukemia].
    Tsubaki M
    Yakugaku Zasshi; 2018; 138(12):1461-1466. PubMed ID: 30504658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
    Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.